Target
Enfortumab vedotin
5 abstracts
Abstract
Cost-effectiveness analysis of contemporary first-line (1L) agents in locally advanced/metastatic urothelial carcinoma (la/mUC).Org: Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, Ziauddin Medical University, Karachi, Pakistan, Canyon Vista Medical Center, Sierra Vista, AZ, University of Arizona, Tucson, AZ, Rashid Latif Medical College, Lahore, Pakistan,
Abstract
Enfortumab vedotin (EV) with pembrolizumab (P) versus chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Analysis of the cisplatin (cis)-ineligible population from EV-302/KEYNOTE-A39.Org: University of California Irvine Medical Center, Santa Creu i Sant Pau Hospital, Seattle Cancer Care Alliance, IDIVAL, Barts Cancer Centre QMUL,
Abstract
First-line (1L) systemic therapy in locally advanced/metastatic urothelial cancer (Ia/mUC): A living interactive systematic review and network meta-analysis.Org: Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, AZ, Division of Hematology and Medical Oncology, Mayo Clinic, Phoeniz, AZ,
Abstract
Treatment patterns of metastatic urothelial cancer in the United States.Org: Johns Hopkins Greenberg Bladder Cancer Institute,
Abstract
Clinician-patient insights and alignment on urothelial carcinoma care.Org: PlatformQ Health Education, Needham, MA, BCAN, Bethesda, MD, Weill Cornell Medical College of Cornell University,